No black box warning on record for Cablivi

As of the latest FDA labeling reviewed, Cablivi (CAPLACIZUMAB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cablivi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hemorrhage: Serious and fatal bleeding can occur. Risk of bleeding is increased in patients with underlying coagulopathies or on concomitant antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt treatment. Withhold CABLIVI 7 days prior to elective surgery, dental procedures, or other invasive interventions. ( 5.1 ) 5.1 Hemorrhage CAB

No black box warning on record for Cablivi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hemorrhage: Serious and fatal bleeding can occur. Risk of bleeding is increased in patients with underlying coagulopathies or on concomitant antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt treatment. Withhold CABLIVI 7 days prior to elective surgery, dental procedures, or other invasive interventions. ( 5.1 ) 5.1 Hemorrhage CAB

Cablivi Black Box Warning

No black box warning on record for Cablivi

Other warnings & precautions

Cablivi Black Box Warning

No black box warning on record for Cablivi

Other warnings & precautions